scholarly journals The Potential of Mycelium and Culture Broth of Lignosus rhinocerotis as Substitutes for the Naturally Occurring Sclerotium with Regard to Antioxidant Capacity, Cytotoxic Effect, and Low-Molecular-Weight Chemical Constituents

PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e102509 ◽  
Author(s):  
Beng Fye Lau ◽  
Noorlidah Abdullah ◽  
Norhaniza Aminudin ◽  
Hong Boon Lee ◽  
Ken Choy Yap ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Antioxidant Capacity ◽  
Cytotoxic Effect ◽  
Chemical Constituents ◽  
Culture Broth ◽  
Low Molecular Weight ◽  
Naturally Occurring ◽  
Lignosus Rhinocerotis

Evaluation of Plasma Low Molecular Weight Antioxidant Capacity by Cyclic Voltammetry

1997 ◽  
Vol 22 (3) ◽  
pp. 411-421 ◽  
Author(s):  
Shlomit Chevion ◽  
Elliot M. Berry ◽  
Nahum Kitrossky ◽  
Ron Kohen
Keyword(s):  
Molecular Weight ◽  
Cyclic Voltammetry ◽  
Antioxidant Capacity ◽  
Low Molecular Weight

scholarly journals Chemical constituents of the physodes of brown algae. Characterization by 1H and 13C nuclear magnetic resonance spectroscopy of oligomers of phloroglucinol from Fucus vesiculosus (L.)

1977 ◽  
Vol 55 (9) ◽  
pp. 1575-1582 ◽  
Author(s):  
James S. Craigie ◽  
A. Gavin McInnes ◽  
Mark A. Ragan ◽  
John A. Walter
Keyword(s):  
Molecular Weight ◽  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Chemical Constituents ◽  
Fucus Vesiculosus ◽  
Resonance Spectroscopy ◽  
Low Molecular Weight ◽  
13C Nuclear Magnetic Resonance ◽  
C Nmr

Alcoholic extracts of Fucus vesiculosus contain small quantities of low molecular weight polyphenols derived from phloroglucinol and 2,2′,4,4′,6,6′-hexahydroxybiphenyl. 1H and 13C nmr were used to identify two of these as 4-(2′′,4′′,6′′-trihydroxyphenoxy)-2,2′,4′,6,6′-pentahydroxybiphenyl and 4-(2′′-(2′′′,4′′′,6′′′-trihydroxyphenoxy)-4′′,6′′-dihydroxyphenoxy)-2,2′,4′, 6,6′-pentanydroxybiphenyl.

Naturally occurring low molecular weight inhibitors of neutral proteinases from PMN-granulocytes and of kallikreins

1978 ◽  
Vol 8 (1-2) ◽  
pp. 57-64 ◽  
Author(s):  
Hans Fritz ◽  
Hans Schiessler ◽  
Reinhard Geiger ◽  
Kjell Ohlsson ◽  
Karl Hochstrasser
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
Naturally Occurring

scholarly journals Naturally occurring low-molecular-weight peptides from the blowfly Phormia regina

1968 ◽  
Vol 110 (4) ◽  
pp. 771-773 ◽  
Author(s):  
R. P. Bodnaryk ◽  
L. Levenbook
Keyword(s):  
Molecular Weight ◽  
Phormia Regina ◽  
Low Molecular Weight ◽  
Naturally Occurring

Freely occurring α-l-aspartyl-l-histidine, β-alanyl-l-histidine (carnosine), α-l-aspartyl-α-l-lysine, l-asparaginyl-α-l-lysine, α-l-glutamyl-α-l-lysine, l-isoleucyl-α-l-lysine, l-seryl-α-l-lysine, l-valyl-α-l-lysine and glycyl-α-l-lysyl-α-l-lysine were identified in young larvae (second and third instars) of the blowfly (Phormia regina).

A prospective, randomized study of low molecular weight as supplemental therapy in metastatic colorectal cancer patients treated with FOLFIRI regimen and target agents.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 746-746
Author(s):  
Hsiang-Lin Tsai ◽  
Chi-Jung Tai ◽  
Ching-Wen Huang ◽  
Jaw-Yuan Wang
Keyword(s):  
Colorectal Cancer ◽  
Molecular Weight ◽  
Adverse Effects ◽  
Metastatic Colorectal Cancer ◽  
Signaling Pathway ◽  
Cytotoxic Effect ◽  
Erk Signaling ◽  
Control Group ◽  
Low Molecular Weight ◽  
Study Group

746 Background: Fucoidan is recently studied for its anti-cancer and anti-inflammatory effects. It also has been used as food supplements in Asia for many years. This study is the first prospective, randomized trial to compare the clinical outcomes and adverse events in metastatic colorectal cancer (mCRC) patients, who are treated with FOLFIRI regimen and target agents as the first line setting with or without low molecular weight Fucoidan (LMF). Additionally, the study also aimed to evaluate the inhibitory effect of LMF in EGFR-KRAS-BRAF-ERK signaling pathway. Methods: A total of 54 patients with mCRC were randomly divided into a study group (28 cases, 4g BID oral low molecular weight Fucoidan powder) and a control group (26 cases, 4g BID oral placebo powder). The supplements were given for 6 months during the therapeutic period. The primary endpoint was the disease-control rate (DCR), and the secondary endpoints were overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse effects between the two groups. MTT cell viability assay and western blotting analysis were used to evaluate synergic effect of LMF plus 5-FU or Cetuximab on Caco-2, SW620 and HCT-15. Results: 54 mCRC patients were enrolled, including 28 patients in the study group and 26 patients in the control group. The DCR was 92.8% vs. 69.2% in study and control group respectively ( P = 0.026) in median follow up time of 11.5 months. The PFS was 15.93 ± 1.20 vs. 10.80 ± 1.06 months ( P = 0.075), ORR was 60.7% vs. 46.2% ( P = 0.284) and OS was 18.04 ± 0.91 vs. 12.96 ± 0.83 months ( P= 0.092). There were no statistical differences in adverse effects between two groups. In vitrostudy, LMF plus 5-FU or Cetuximab showed synergic cytotoxic effect (maximal 24% increase) through the inhibition of the expression of p-EGFR, p-ERK and p-Akt. Conclusions: The preliminary results show that LMF as supplemental therapy in mCRC patients may improve DCR. In vitro, Fucoidan showed the synergic cytotoxic effect with 5-FU or Cetuximab. The possible mechanism may involve the inhibition effect of Fucoidan in phosphorylation of EGFR-KRAS-BRAF-ERK signaling pathway.

Sign in / Sign up

Export Citation Format

Share Document